NCT07899463 ESR1 Mutations in Metastatic Hormone Receptor-Positive Breast Cancer in the Greek Population
| NCT ID | NCT07899463 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Hellenic Cooperative Oncology Group |
| Condition | ESR1 Gene Mutation |
| Study Type | OBSERVATIONAL |
| Enrollment | 500 participants |
| Start Date | 2025-05-13 |
| Primary Completion | 2027-05-15 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 500 participants in total. It began in 2025-05-13 with a primary completion date of 2027-05-15.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this observational study is to assess the prevalence of ESR1 mutations in patients with metastatic hormone receptor-positive/HER2-negative breast cancer in Greece and evaluate the associations of these mutations with disease characteristics, clinical outcomes and real-world treatment patterns. This study will include participants who have already undergone ESR1 testing as part of their standard medical care. Patient real-world data will be extracted by the patient's medical records. No additional procedures or visits beyond routine care will be required. Data will be collected from routine clinical visits and standard-of-care treatment.
Eligibility Criteria
Inclusion Criteria: * Male or female patients, regardless of race, residing in Greece, aged 18 years or older at the start of treatment. Patients with histologically confirmed metastatic breast cancer with positive hormone receptors and negative HER2 status. Patients undergoing ESR1 mutation testing. Exclusion Criteria: * Patients with metastatic hormone receptor-positive breast cancer who have not undergone ESR1 mutation testing.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07899463 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying ESR1 Gene Mutation. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07899463 currently recruiting?
Yes, NCT07899463 is actively recruiting participants. Contact the research team at eleni_galani@yahoo.gr for enrollment information.
Where is the NCT07899463 trial being conducted?
This trial is being conducted at Athens, Greece.
Who is sponsoring the NCT07899463 clinical trial?
NCT07899463 is sponsored by Hellenic Cooperative Oncology Group. The trial plans to enroll 500 participants.